Skip to main content
Premium Trial:

Request an Annual Quote

Medison to Market CardioDx's Corus CAD in Israel

NEW YORK (GenomeWeb News) – Medison will make available CardioDx's Corus CAD diagnostic test for obstructive coronary artery disease in Israel as part of an agreement announced today.

Under the terms of the deal, Medison will market and sell Corus CAD in Israel, where heart disease is the second-leading cause of death and responsible for 16 percent of all deaths annually, the companies said. Blood samples from patients in Israel will be shipped to CardioDx's CLIA-certified laboratory in Palo Alto, Calif., for analysis and test reporting.

Financial and other terms of the deal were not disclosed.

Corus CAD is a gene expression test for assessing obstructive CAD in non-diabetic patients. CardioDx said it is the only sex-specific test for diagnosing obstructive CAD "that accounts for critical biological differences between men and women," to help physicians in the early determination of potential obstructive CAD.

A recent study published in the Journal of the American Board of Family Medicine found that Corus CAD had a significant impact on decisions by doctors in the primary care setting and changed their treatment strategies, as Pharmacogenomics Reporter reported.

In October, CardioDx filed with the US Securities and Exchange Commission to go public. With its shares anticipated to fetch between $14 and $16 per share, its planned initial public offering is expected to raise about $92 million, the firm said.